ArticleCancer chemotherapy and pharmacology2026
Glucarpidase efficacy in mitigating methotrexate toxicity is unaffected by concurrent administration of folinic acid.
Article in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHigh-dose methotrexate (HDMTX) is a cornerstone in pediatric oncology, but delayed methotrexate elimination (DME) can cause severe toxicity. Rescue therapy typically combines folinic acid (FA) and glucarpidase (GP), yet current guidelines recommend pausing FA around GP administration due to presumed interference. This study aimed to determine whether FA affects GP efficacy in metabolizing methotrexate and to assess the impact on folate metabolites.
methodsAn ex vivo model was developed using human plasma spiked with clinically relevant concentrations of methotrexate and FA, with or without GP. Samples were analyzed by mass spectrometry to quantify methotrexate, FA, and related metabolites. Additional experiments included blood from pediatric patients receiving HDMTX per ALLTogether protocol.
resultsGP rapidly metabolized > 99% of methotrexate across all tested conditions, regardless of FA presence, producing robust DAMPA levels. FA degradation by GP was observed at varying levels, ranging from 8 to 78%. Patient samples confirmed efficient methotrexate clearance by GP, with similar DAMPA production whether FA was present or absent.
conclusionConcurrent FA administration does not compromise GP efficacy in neutralizing methotrexate. These findings challenge current recommendations to suspend FA around GP dosing and suggest that continuous FA rescue may be safe and beneficial. Adjustments to FA dosing post-GP may be warranted due to partial FA degradation. Further clinical studies should refine rescue strategies to optimize efficacy and minimize toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.